Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f
- 26 November 2009
- journal article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 122 (1), 58-62
- https://doi.org/10.1111/j.1600-0404.2009.01267.x
Abstract
To assess possible improved efficacy of Boron Neutron Capture Therapy (BNCT) for glioblastoma multiforme (GBM) using prolonged infusion and a correspondingly higher dose of l-boronophenylalanine, as the fructose complex (BPA-f). The benefit of prolonged infusion was analyzed by comparing the results from a Phase II study using 6 h infusion of BPA-f with those obtained from a Phase I/II study using 2 h of infusion. Median survival time (MST) from diagnosis, patient baseline characteristics, salvage treatment and severe adverse events were considered in the comparison. MST increased significantly, from 12.8 (95% confidence interval or CI: 10.3-14.0) months with 2 h infusion to 17.7 (95% CI: 13.6-19.9) months with 6 h of infusion. The fraction of patients with WHO grade 3-4 adverse events was similar in the two studies at 13% and 14%, respectively. Prolonged infusion was found to be beneficial for the efficacy of BNCT and it is suggested that 6 h infusion of BPA-f should be used in future trials of BNCT for GBM. BNCT, which is a single-day treatment with mild side effects, should be assessed in a controlled trial, as an alternative to 30 daily fractions of conventional fractionated photon therapy over a period of 6 weeks.Keywords
This publication has 18 references indexed in Scilit:
- Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA)Radiotherapy and Oncology, 2008
- Management of Malignant Glioma – Quo Vadis?Onkologie, 2008
- Boron neutron capture therapy for the treatment of glioblastomas and extracranial tumours: As effective, more effective or less effective than photon irradiation?Radiotherapy and Oncology, 2007
- Therapeutic options for recurrent high-grade glioma in adult patients: Recent advancesCritical Reviews in Oncology/Hematology, 2006
- Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized TrialJournal of Clinical Oncology, 2006
- Boron Neutron Capture Therapy of Cancer: Current Status and Future ProspectsClinical Cancer Research, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Boron neutron capture therapy for glioblastoma multiforme: clinical studies in SwedenJournal of Neuro-Oncology, 2003
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma TrialsJNCI Journal of the National Cancer Institute, 1993